Novavax Inc

NVAX is consolidating in a neutral to cautious phase within its Stage 2 uptrend, trading between the 9- and 20-day EMAs after a pullback from early-September highs. The long-term trend remains up above the 50- and 200-day SMAs, but short-term momentum has cooled with RSI near 58 and moderate Options Score. Under a speculative strategy, execution favors deferred entries on pullback acceptance into the EMA support zone, avoiding premature buys until clear support is confirmed.

• ↑Sanofi partnership expands licensed reach toward a $100B-plus vaccine market
• ↑Q2 product sales up 76% YoY to $19M, driven by Matrix-M adjuvant
• ↓Q2 revenue plunged to $57M from $239M YoY, showing high fluctuation